Movement Alert｜Iovance Biotherapeutics Intraday Decline 5.27%, New CMO Appointment Follows Sharp Rally

Market Focus

Oct 06

On October 6, Iovance Biotherapeutics, Inc. fell 5.27% in regular trading, trading at $13.335 per share with turnover of $42.9533 million. The decline followed the company's October 1 announcement appointing Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer, which came after a sharp rally exceeding 35% triggered by raised 2026 revenue guidance.

The company recently lifted its 2026 revenue outlook to $410 million to $420 million, up from $350 million to $370 million, citing strong U.S. demand for Amtagvi and Proleukin. Analyst estimates had averaged $402.8 million. The CMO appointment, made during a period of rapid share appreciation, prompted profit-taking as the market consolidated recent gains.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocytes for metastatic melanoma and other solid tumor cancers in the United States. Its portfolio includes Amtagvi, Proleukin, and multiple pipeline candidates for lung and gynecological cancers.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/news/1198544421"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1198544421\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1198544421?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-06 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198544421","market":"us","top_or_hot":-1,"title":"Movement Alert｜Iovance Biotherapeutics Intraday Decline 5.27%, New CMO Appointment Follows Sharp Rally","media":"Market Focus","content":"<p><p>On October 6, Iovance Biotherapeutics, Inc. fell 5.27% in regular trading, trading at $13.335 per share with turnover of $42.9533 million. The decline followed the company's October 1 announcement appointing Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer, which came after a sharp rally exceeding 35% triggered by raised 2026 revenue guidance.</p><p>The company recently lifted its 2026 revenue outlook to $410 million to $420 million, up from $350 million to $370 million, citing strong U.S. demand for Amtagvi and Proleukin. Analyst estimates had averaged $402.8 million. The CMO appointment, made during a period of rapid share appreciation, prompted profit-taking as the market consolidated recent gains.</p><p>Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocytes for metastatic melanoma and other solid tumor cancers in the United States. Its portfolio includes Amtagvi, Proleukin, and multiple pipeline candidates for lung and gynecological cancers.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Iovance Biotherapeutics Intraday Decline 5.27%, New CMO Appointment Follows Sharp Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Iovance Biotherapeutics Intraday Decline 5.27%, New CMO Appointment Follows Sharp Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-06 22:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 6, Iovance Biotherapeutics, Inc. fell 5.27% in regular trading, trading at $13.335 per share with turnover of $42.9533 million. The decline followed the company's October 1 announcement appointing Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer, which came after a sharp rally exceeding 35% triggered by raised 2026 revenue guidance.</p><p>The company recently lifted its 2026 revenue outlook to $410 million to $420 million, up from $350 million to $370 million, citing strong U.S. demand for Amtagvi and Proleukin. Analyst estimates had averaged $402.8 million. The CMO appointment, made during a period of rapid share appreciation, prompted profit-taking as the market consolidated recent gains.</p><p>Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocytes for metastatic melanoma and other solid tumor cancers in the United States. Its portfolio includes Amtagvi, Proleukin, and multiple pipeline candidates for lung and gynecological cancers.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"","article_id":"1198544421","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198544421","pubTimestamp":1791295649,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 6, Iovance Biotherapeutics, Inc. fell 5.27% in regular trading, trading at $13.335 per share with turnover of $42.9533 million. The decline followed the company's October 1 announcement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"走势警报|Iovance Biotherapeutics 盘中下跌 5.27%，新 CMO 任命紧随大幅反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"On October 6, Iovance Biotherapeutics, Inc. fell 5.27% in regular trading, trading at $13.335 per share with turnover of $42.9533 million. The decline followed the company's October 1 announcement appointing Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer, which came after a sharp rally exceeding 35% triggered by raised 2026 revenue guidance.The company recently lifted its 2026 revenue outlook to $410 million to $420 million, up from $350 million to $370 million, citing strong U.S. demand for Amtagvi and Proleukin. Analyst estimates had averaged $402.8 million. The CMO appointment, made during a period of rapid share appreciation, prompted profit-taking as the market consolidated recent gains.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocytes for metastatic melanoma and other solid tumor cancers in the United States. Its portfolio includes Amtagvi, Proleukin, and multiple pipeline candidates for lung and gynecological cancers.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}